A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation

Tatyana V Turti, Elena N Baibarina, Elena A Degtiareva, Elena S Keshishyan, Yurii V Lobzin, Leyla S Namazova-Вaranova, Andrey P Prodeus, Konstantin M Gudkov, Anna I Kruglova, Gregory A Schulz, Gerard F Notario, Tatyana V Turti, Elena N Baibarina, Elena A Degtiareva, Elena S Keshishyan, Yurii V Lobzin, Leyla S Namazova-Вaranova, Andrey P Prodeus, Konstantin M Gudkov, Anna I Kruglova, Gregory A Schulz, Gerard F Notario

Abstract

Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTIs) in children globally. Predisposing conditions for the development of serious RSV disease include preterm infants and those with cardiopulmonary illness, including congenital heart disease (CHD) and bronchopulmonary dysplasia (BPD). No vaccine is currently approved for the prevention of RSV infection. It is recommended that children at high risk be prophylactically administered palivizumab, a monoclonal antibody that has been shown in a number of clinical studies to reduce hospitalization rates due to serious RSV infection. The objective of the current study was to determine the safety and effectiveness of palivizumab in preventing serious RSV disease in high-risk children in the Russian Federation. Children at high risk of serious RSV disease (ie, born at ≤ 35 wk gestational age and ≤ 6 mo of age, and/or aged ≤ 24 mo with BPD or hemodynamically significant CHD) were enrolled. Subjects were to receive 3 to 5 monthly injections of palivizumab 15 mg/kg (depending on the month of the initial injection) over the RSV season. The primary endpoint was RSV-related hospitalizations. Adverse events (AEs) were reported through 100 days following the final injection.

Results: One hundred subjects received ≥ 1 injection of palivizumab; 94 completed their dosing schedule. There were no RSV hospitalizations or deaths. Six of 7 subjects hospitalized for respiratory/cardiac conditions had an RSV test, which was negative in all cases. Three non-serious AEs (acute intermittent rhinitis and rhinitis, 1 subject; atopic dermatitis, 1 subject) were considered possibly related to palivizumab. All other AEs were mild or moderate and considered not related/probably not related to palivizumab.

Conclusion: Palivizumab was generally well tolerated and effectively prevented serious RSV infection in a mixed population of high-risk children in the Russian Federation.

Trial registration: ClinicalTrials.gov: NCT01006629.

Figures

Figure 1
Figure 1
Number of subjects meeting criteria for high risk of serious RSV disease (N = 100). BPD = bronchopulmonary dysplasia; HSCHD = hemodynamically significant congenital heart disease; RSV = respiratory syncytial virus; wGA = weeks gestational age.
Figure 2
Figure 2
(A) Household conditions and (B) exposure to tobacco smoke (N = 100). *n = 47.

References

    1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O’Brien KL, Roca A, Wright PF, Bruce N. et al.Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545–1555. doi: 10.1016/S0140-6736(10)60206-1.
    1. Tatochenko V, Uchaikin V, Gorelov A, Gudkov K, Campbell A, Schulz G, Prahl R, Notario G. Epidemiology of respiratory syncytial virus in children </=2 years of age hospitalized with lower respiratory tract infections in the Russian Federation: a prospective, multicenter study. Clin Epidemiol. 2010;2:221–227.
    1. Oshansky CM, Zhang W, Moore E, Tripp RA. The host response and molecular pathogenesis associated with respiratory syncytial virus infection. Future Microbiol. 2009;4(3):279–297. doi: 10.2217/fmb.09.1.
    1. Stollenwerk N, Harper RW, Sandrock CE. Bench-to-bedside review: rare and common viral infections in the intensive care unit–linking pathophysiology to clinical presentation. Crit Care. 2008;12(4):219. doi: 10.1186/cc6917.
    1. Empey KM, Peebles RS Jr, Kolls JK. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin Infect Dis. 2010;50(9):1258–1267. doi: 10.1086/651603.
    1. Tregoning JS, Schwarze J. Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin Microbiol Rev. 2010;23(1):74–98. doi: 10.1128/CMR.00032-09.
    1. Blanco JC, Boukhvalova MS, Shirey KA, Prince GA, Vogel SN. New insights for development of a safe and protective RSV vaccine. Hum Vaccin. 2010;6(6):482–492. doi: 10.4161/hv.6.6.11562.
    1. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O’Grady J, Koenig S, Tamura JK. et al.Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997;176(5):1215–1224. doi: 10.1086/514115.
    1. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102(3):531–537.
    1. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr, Connor EM, Sondheimer HM. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143(4):532–540. doi: 10.1067/S0022-3476(03)00454-2.
    1. Grimaldi M, Gouyon B, Sagot P, Quantin C, Huet F, Gouyon JB. Palivizumab efficacy in preterm infants with gestational age < or = 30 weeks without bronchopulmonary dysplasia. Pediatr Pulmonol. 2007;42(3):189–192. doi: 10.1002/ppul.20503.
    1. Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J. 2003;22(9):823–827. doi: 10.1097/01.inf.0000086403.50417.7c.
    1. Mitchell I, Paes BA, Li A, Lanctot KL. CARESS: The Canadian Registry of Palivizumab. Pediatr Infect Dis J. 2011;30(8):651–655. doi: 10.1097/INF.0b013e31821146f7.
    1. Romero JR. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Pediatr Infect Dis J. 2003;22(2 Suppl):S46–S54.
    1. Singleton R, Dooley L, Bruden D, Raelson S, Butler JC. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants. Pediatr Infect Dis J. 2003;22(6):540–545.
    1. Henckel E, Luthander J, Berggren E, Kapadia H, Naver L, Norman M, Bennet R, Eriksson M. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002. Pediatr Infect Dis J. 2004;23(1):27–31. doi: 10.1097/01.inf.0000105106.93562.d3.
    1. Morris SK, Dzolganovski B, Beyene J, Sung L. A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection. BMC Infect Dis. 2009;9:106. doi: 10.1186/1471-2334-9-106.
    1. From the American Academy of Pediatrics. Policy statements–modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124(6):1694–1701.
    1. Langley GF, Anderson LJ. Epidemiology and prevention of respiratory syncytial virus infections among infants and young children. Pediatr Infect Dis J. 2011;30(6):510–517.
    1. Law BJ, Langley JM, Allen U, Paes B, Lee DS, Mitchell I, Sampalis J, Walti H, Robinson J, O’Brien K. et al.The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J. 2004;23(9):806–814. doi: 10.1097/.
    1. Weber MW, Milligan P, Hilton S, Lahai G, Whittle H, Mulholland EK, Greenwood BM. Risk factors for severe respiratory syncytial virus infection leading to hospital admission in children in the western region of The Gambia. Int J Epidemiol. 1999;28(1):157–162. doi: 10.1093/ije/28.1.157.
    1. Shafey O, Eriksen M, Ross H, Mackay J. The Tobacco Atlas. 3. American Cancer Society; Available at: . Accessed May 12, 2011.
    1. Gannon JC. Global infectious disease threat and its implications for the United States. National Intelligence Council, Washington, DC; 2000.
    1. WHO Health Status Statistics: Mortality. Available at: Accessed May 12, 2011.
    1. Wuhib T, McCarthy BJ, Chorba TL, Sinitsina TA, Ivasiv IV, McNabb SJ. Underestimation of infant mortality rates in one republic of the former Soviet Union. Pediatrics. 2003;111(5 Pt 1):e596–e600.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren